Donald Trump's first term advanced rules mandating healthcare price transparency. Employers fear backtracking during his ...

Amid uncertainty about the future of such requirements, some health policy experts think it’s unlikely the incoming Trump ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares.

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...